United States · 
What does venBio Partners invest in?
venBio Partners invests most often at Series A and Series B (71% of the rounds on record), in sectors such as Android, Semiconductor and Business Development.
venBio Partners highlights
- 01
28 rounds on record
- 02
Mostly Series A and Series B: 71% of its rounds
- 03
Led 1 rounds
- 04
2 exits from the portfolio
What they do
Filed 4 private fund offerings with the SEC, the most recent in 2021-05From their own website
- Type
- VC firm (from a list, unverified)
- Cheque size
- Not stated
- Stages
- GrowthPre-IPOSeedSeries A
- Sectors
- AndroidSemiconductorBusiness Development
- Based in
- San Francisco, United States
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first28 appearances
- 2024
1 round
- Sept
- 2019
3 rounds
- Oct
- Sept
- Apr
- 2018
5 rounds
- Dec
- Dec
- Dec
- Jun
- Jun
- 2017
4 rounds
- Dec
- Oct
- Jun
- Jan
- 2016
1 round
- Dec
- 2015
6 rounds
- Sept
- Aug
- Aug
- Jul
- May
- Feb
- 2014
4 rounds
- Sept
- Aug
- Apr
- Feb
- 2013
2 rounds
- Jan
- Jan
- 2012
2 rounds
- Dec
- Oct
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration9 named
ARAaron RoystonPartner of venBio Partners LLCiFiling they signed
ADAntoinette DelhonteChief Financial OfficeriForm ADV
CSCorey S. GoodmanDirector of the General PartneriFiling they signed
DPDavid PezeshkiChief Financial Officer of venBio Partners LLCiFiling they signed
KVKurt von EmsterDirector of the General PartneriFiling they signed
PBPaul BrookeDirector of the General PartneriFiling they signed
RSRichard Samuel GasterExecutive OfficeriFiling they signed
RARobert AdelmanDirector of the General PartneriFiling they signed
YYYvonne YamanakaExecutive OfficeriFiling they signed
We also hold 9 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What the register says
From the firm's own filings with the SEC, which it must file accurately by law
$1.8Bgross assets of its fundsOct 2026
Exemptreporting adviserventure or small private funds
- Legal name
- Venbio Partners LLC
- SEC number
- CRD 290045
Exits from the portfolio
Companies it backed that were later bought or listed2 in all
Labrys BiologicsBought by Teva Pharmaceutical Industries$825MJun 2014
Aragon PharmaceuticalsBought by Johnson & Johnson$1.0BJun 2013
An exit counts when it came after the firm's first round in the company. From historical deal records.